Legal Regulation of Access to Unauthorised Medicines for Patients Suffering from Rare Diseases
##plugins.themes.bootstrap3.article.main##
Abstract
In the European Union (EU), medicines can be marketed only after they have been authorised. However, some medicines need to be accessible before they have been authorised. This especially applies to medicines, which are expected to benefit severely ill patients who cannot be treated with authorised medicines or who have a disease for which no medicine has been authorised yet. The treatment with unauthorised medicines may be the last chance for patients who suffer from rare diseases and cannot enrol in an ongoing clinical trial or be treated with a potentially life-saving medicine. The aim of this article is to analyse the aspects of the legal regulation of access to unauthorised medicines for such patients. The fact that 27–36 million patients with rare diseases live in the EU and there are approximately 200,000–240,000 of such patients in Lithuania underlines the relevance of the study.
##plugins.themes.bootstrap3.article.details##
Section
Articles
Authors contributing to Societal Sciences agree to publish their articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public Licence (CC BY-NC-ND), allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this licence are made clear.
Authors retain copyright of their work, with first publication rights granted to the Association for Learning Technology.
Authors retain copyright of their work, with first publication rights granted to the Association for Learning Technology.
